Compare SNAP & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNAP | BBIO |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.5B |
| IPO Year | 2017 | 2019 |
| Metric | SNAP | BBIO |
|---|---|---|
| Price | $7.63 | $72.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 26 | 19 |
| Target Price | $10.40 | ★ $74.79 |
| AVG Volume (30 Days) | ★ 58.8M | 2.2M |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,772,269,000.00 | $353,780,000.00 |
| Revenue This Year | $12.00 | $123.32 |
| Revenue Next Year | $10.64 | $73.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.75 | ★ 62.46 |
| 52 Week Low | $6.90 | $25.34 |
| 52 Week High | $13.28 | $72.28 |
| Indicator | SNAP | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 71.63 |
| Support Level | $7.56 | $64.41 |
| Resistance Level | $8.30 | $67.71 |
| Average True Range (ATR) | 0.33 | 2.70 |
| MACD | -0.09 | 0.36 |
| Stochastic Oscillator | 4.46 | 95.21 |
Snap is a technology company best known for its marquis social media application. Snapchat, a visual messaging application that has amassed hundreds of millions of users. The app was initially only used to communicate with family and friends through photographs and short videos (known as "Snaps"). Users can now enjoy augmented reality, or AR, lenses, content from famous creators and celebrities, updates about local events, and more. Although the app offers a paid subscription option with premium features, advertising sales produce most of the app's revenue. The firm also sells wearable devices called AR Spectacles, which can capture photos and videos overlayed with AR lenses, but these make up a small portion of Snap's overall sales.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.